301 related articles for article (PubMed ID: 22980449)
21. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
22. Use of conventional, complementary, and alternative treatments for pain among individuals seeking primary care treatment with buprenorphine-naloxone.
Barry DT; Savant JD; Beitel M; Cutter CJ; Moore BA; Schottenfeld RS; Fiellin DA
J Addict Med; 2012 Dec; 6(4):274-9. PubMed ID: 23041680
[TBL] [Abstract][Full Text] [Related]
23. Reducing the health consequences of opioid addiction in primary care.
Bowman S; Eiserman J; Beletsky L; Stancliff S; Bruce RD
Am J Med; 2013 Jul; 126(7):565-71. PubMed ID: 23664112
[TBL] [Abstract][Full Text] [Related]
24. Managing co-occurring substance use and pain disorders.
Miotto K; Kaufman A; Kong A; Jun G; Schwartz J
Psychiatr Clin North Am; 2012 Jun; 35(2):393-409. PubMed ID: 22640762
[TBL] [Abstract][Full Text] [Related]
25. Primary care patient characteristics associated with completion of 6-month buprenorphine treatment.
Neumann AM; Blondell RD; Azadfard M; Nathan G; Homish GG
Addict Behav; 2013 Nov; 38(11):2724-8. PubMed ID: 23934003
[TBL] [Abstract][Full Text] [Related]
26. The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.
Mammen K; Bell J
Expert Opin Pharmacother; 2009 Oct; 10(15):2537-44. PubMed ID: 19708849
[TBL] [Abstract][Full Text] [Related]
27. Comparisons of analgesic potency and side effects of buprenorphine and buprenorphine with ultra-low-dose naloxone.
Ling W; Hillhouse M; Jenkins J; Miotto K; Torrington M; Chapleo C
J Addict Med; 2012 Jun; 6(2):118-23. PubMed ID: 22475985
[TBL] [Abstract][Full Text] [Related]
28. Group medication management for buprenorphine/naloxone in opioid-dependent veterans.
Berger R; Pulido C; Lacro J; Groban S; Robinson S
J Addict Med; 2014; 8(6):415-20. PubMed ID: 25275875
[TBL] [Abstract][Full Text] [Related]
29. Aberrant behaviors in a primary care-based cohort of patients with chronic pain identified as misusing prescription opioids.
Cheatle MD; O'Brien CP; Mathai K; Hansen M; Grasso M; Yi P
J Opioid Manag; 2013; 9(5):315-24. PubMed ID: 24353044
[TBL] [Abstract][Full Text] [Related]
30. Who benefits from additional drug counseling among prescription opioid-dependent patients receiving buprenorphine-naloxone and standard medical management?
Weiss RD; Griffin ML; Potter JS; Dodd DR; Dreifuss JA; Connery HS; Carroll KM
Drug Alcohol Depend; 2014 Jul; 140():118-22. PubMed ID: 24831754
[TBL] [Abstract][Full Text] [Related]
31. Consensus statement on office-based treatment of opioid dependence using buprenorphine.
Fiellin DA; Kleber H; Trumble-Hejduk JG; McLellan AT; Kosten TR
J Subst Abuse Treat; 2004 Sep; 27(2):153-9. PubMed ID: 15450648
[TBL] [Abstract][Full Text] [Related]
32. Buprenorphine-naloxone therapy in pain management.
Chen KY; Chen L; Mao J
Anesthesiology; 2014 May; 120(5):1262-74. PubMed ID: 24509068
[TBL] [Abstract][Full Text] [Related]
33. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users.
Alho H; Sinclair D; Vuori E; Holopainen A
Drug Alcohol Depend; 2007 Apr; 88(1):75-8. PubMed ID: 17055191
[TBL] [Abstract][Full Text] [Related]
34. The problem of pain: Additive analgesic effect of tramadol and buprenorphine in a patient with opioid use disorder.
Montalvo C; Genovese N; Renner J
Subst Abus; 2019; 40(2):136-139. PubMed ID: 30835647
[No Abstract] [Full Text] [Related]
35. Improving use of narcotics for nonmalignant chronic pain: a lesson from Community Care of North Carolina.
Bujold E; Huff J; Staton EW; Pace WD
J Opioid Manag; 2012; 8(6):363-7. PubMed ID: 23264314
[TBL] [Abstract][Full Text] [Related]
36. When opioids fail in chronic pain management: the role for buprenorphine and hospitalization.
Berland DW; Malinoff HL; Weiner MA; Przybylski R
Am J Ther; 2013; 20(4):316-21. PubMed ID: 23584313
[TBL] [Abstract][Full Text] [Related]
37. Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence.
Turner BJ; Laine C; Lin YT; Lynch K
Arch Intern Med; 2005 Aug 8-22; 165(15):1769-76. PubMed ID: 16087826
[TBL] [Abstract][Full Text] [Related]
38. Time to include buprenorphine-naloxone combination in the WHO Model List of Essential Medicines.
Balhara YP
J Opioid Manag; 2013; 9(4):237. PubMed ID: 24380101
[No Abstract] [Full Text] [Related]
39. Prolonged-release oxycodone/naloxone in the treatment of neuropathic pain - results from a large observational study.
Hermanns K; Junker U; Nolte T
Expert Opin Pharmacother; 2012 Feb; 13(3):299-311. PubMed ID: 22224497
[TBL] [Abstract][Full Text] [Related]
40. Physician-pharmacist collaborative care model for buprenorphine-maintained opioid-dependent patients.
DiPaula BA; Menachery E
J Am Pharm Assoc (2003); 2015; 55(2):187-92. PubMed ID: 25749264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
